SCHEMBL25751649

SCHEMBL25751649

CC(C)(C)N=C(N1CCCC1)N1CCOCC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.41
TP53 P04637 1/20 0.41
KMT2A Q03164 1/20 0.41
SMN1; SMN2 Q16637 4/20 0.39
USP2 O75604 1/20 0.39
PDK1 Q15118 2/20 0.37
PDK2 Q15119 2/20 0.37
PDK3 Q15120 2/20 0.37
ALDH1A1 P00352 2/20 0.36
PKM P14618 1/20 0.35
ALPG P10696 1/20 0.35
CA12 O43570 3/20 0.34
CA1 P00915 3/20 0.34
CA9 Q16790 3/20 0.34
CA2 P00918 2/20 0.34
LMNA P02545 1/20 0.34
FAAH O00519 1/20 0.33
PHGDH O43175 1/20 0.33
ALDH2 P05091 1/20 0.33
MGLL Q99685 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25751645 0.94 SMN1; SMN2 (0.42) MEN1TP53KMT2ASMN1; SMN2USP2
SCHEMBL25751644 0.87 ALDH1A1 (0.32) TP53SMN1; SMN2ALDH1A1CA12CA1
SCHEMBL25751710 0.85 ALDH1A1 (0.35) MEN1TP53KMT2ASMN1; SMN2ALDH1A1
SCHEMBL25751651 0.85 SMN1; SMN2 (0.37) MEN1TP53KMT2ASMN1; SMN2USP2
SCHEMBL25751707 0.83 MEN1 (0.31) MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL25751702 0.78
SCHEMBL25751654 0.78 CYP1A2 (0.37) KMT2AALDH1A1LMNAPHGDHMGLL
SCHEMBL24051517 0.77 MEN1 (0.45) MEN1TP53KMT2ASMN1; SMN2USP2
SCHEMBL12562452 0.75 SMN1; SMN2 (0.45) MEN1TP53KMT2ASMN1; SMN2USP2
SCHEMBL25753750 0.72 SMN1; SMN2 (0.43) MEN1TP53KMT2ASMN1; SMN2PDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240026358-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2024-01-25 US disclosed
US-20240026358-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2024-01-25 US disclosed
US-20230203484-A1 DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO WAVE LIFE SCIENCES LTD. (SG) 2023-06-29 US disclosed
US-20230203484-A1 DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO WAVE LIFE SCIENCES LTD. (SG) 2023-06-29 US disclosed
US-20230203087-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2023-06-29 US disclosed
US-20230203087-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2023-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203087-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF RNGTT, NSUN2, ALKBH1 MEN1 3176/4885TP53 1305/4885KMT2A 742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.